Figure 1From: Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany Decision tree comparing two alternative strategies: Prospective HLA-B*5701-screening prior to using abacavir/lamivudine FDC as part of an antiretroviral treatment regimen versus initiation of abacavir/lamivudine FDC without genetic screening.Back to article page